A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis

Administered By

Awarded By

Contributors

Start/End

  • January 20, 2021 - January 17, 2024